Ultragenyx Pharmaceutical Inc. announced that Mardi Dier, Executive Vice President, is leaving the company, effective November 15, 2022, to assume the dual role of CFO and Chief Business Development Officer at privately held ACELYRIN, INC. Ted Huizenga, Chief Accounting Officer, and Aaron Olsen, Senior Vice President of Corporate Strategy and Finance, will lead ongoing finance activities during the search for a successor.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.12 USD | +0.37% | -1.06% | -14.01% |
14/05 | Korro Bio Q1 Net Loss Shrinks; Kemi Olugemo Appointed as Chief Medical Officer | MT |
03/05 | Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $47 From $48, Keeps Neutral Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.01% | 340.34Cr | |
+7.52% | 11TCr | |
+11.38% | 11TCr | |
-12.64% | 2.22TCr | |
+0.44% | 2.13TCr | |
-4.18% | 1.9TCr | |
-37.85% | 1.85TCr | |
-8.58% | 1.68TCr | |
+37.41% | 1.25TCr | |
-23.95% | 808.97Cr |
- Stock Market
- Equities
- RARE Stock
- News Ultragenyx Pharmaceutical Inc.
- Ultragenyx Pharmaceutical Inc. Announces Departure of Mardi Dier, Executive Vice President